Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

PANTOTHENATE FOR PEAK IDENTIFICATION CRS (10 MG)

PANTOTHENATE FOR PEAK IDENTIFICATION CRS (10 MG)

ND

DISCOVER
FENOTEROL FOR SYSTEM SUITABILITY CRS (0.13 MG)

FENOTEROL FOR SYSTEM SUITABILITY CRS (0.13 MG)

ND

DISCOVER
NILOTINIB IMPURITY A CRS (20 MG)

NILOTINIB IMPURITY A CRS (20 MG)

ND

DISCOVER
OCTREOTIDE CRS (11 MG)

OCTREOTIDE CRS (11 MG)

ND

DISCOVER
OCTREOTIDE FOR NMR IDENTIFICATION CRS (2 MG)

OCTREOTIDE FOR NMR IDENTIFICATION CRS (2 MG)

ND

DISCOVER
OCTREOTIDE IMPURITY MIXTURE CRS (0.01 MG)

OCTREOTIDE IMPURITY MIXTURE CRS (0.01 MG)

ND

DISCOVER
MEBEVERINE FOR SYSTEM SUITABILITY CRS (1.02 MG)

MEBEVERINE FOR SYSTEM SUITABILITY CRS (1.02 MG)

ND

DISCOVER
NILOTINIB IMPURITY C CRS (20 MG)

NILOTINIB IMPURITY C CRS (20 MG)

ND

DISCOVER
PANTOLACTONE CRS (10 MG)

PANTOLACTONE CRS (10 MG)

ND

DISCOVER
INFLIXIMAB BRP (25 MG)

INFLIXIMAB BRP (25 MG)

ND

DISCOVER
NILOTINIB IMPURITY B CRS (25 MG)

NILOTINIB IMPURITY B CRS (25 MG)

ND

DISCOVER
DRONEDARONE  IMPURITY B CRS (10 MG)

DRONEDARONE IMPURITY B CRS (10 MG)

ND

DISCOVER